- Home
- ACXP vs ORKT Comparison
ACXP vs ORKT Comparison
Compare ACXP & ORKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- ORKT
- Stock Information
- Founded
- ACXP 2017
- ORKT 2003
- Country
- ACXP United States
- ORKT Singapore
- Employees
- ACXP N/A
- ORKT N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- ORKT
- Sector
- ACXP Health Care
- ORKT
- Exchange
- ACXP Nasdaq
- ORKT NYSE
- Market Cap
- ACXP 8.4M
- ORKT N/A
- IPO Year
- ACXP 2021
- ORKT 2024
- Fundamental
- Price
- ACXP $0.49
- ORKT $0.59
- Analyst Decision
- ACXP Strong Buy
- ORKT Strong Buy
- Analyst Count
- ACXP 2
- ORKT 1
- Target Price
- ACXP $10.00
- ORKT $5.00
- AVG Volume (30 Days)
- ACXP 18.6M
- ORKT 264.8K
- Earning Date
- ACXP 08-08-2025
- ORKT 01-01-0001
- Dividend Yield
- ACXP N/A
- ORKT N/A
- EPS Growth
- ACXP N/A
- ORKT N/A
- EPS
- ACXP N/A
- ORKT N/A
- Revenue
- ACXP N/A
- ORKT $2,962,282.00
- Revenue This Year
- ACXP N/A
- ORKT $9.63
- Revenue Next Year
- ACXP N/A
- ORKT N/A
- P/E Ratio
- ACXP N/A
- ORKT N/A
- Revenue Growth
- ACXP N/A
- ORKT N/A
- 52 Week Low
- ACXP $0.30
- ORKT $0.40
- 52 Week High
- ACXP $3.33
- ORKT $8.00
- Technical
- Relative Strength Index (RSI)
- ACXP 51.70
- ORKT N/A
- Support Level
- ACXP $0.46
- ORKT N/A
- Resistance Level
- ACXP $0.56
- ORKT N/A
- Average True Range (ATR)
- ACXP 0.10
- ORKT 0.00
- MACD
- ACXP -0.01
- ORKT 0.00
- Stochastic Oscillator
- ACXP 25.55
- ORKT 0.00
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.